 Michel Chonchol
Concepts (681)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 80 | 2023 | 486 | 10.910 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 29 | 2023 | 209 | 8.480 |
Why?
| | Kidney Failure, Chronic | 55 | 2023 | 489 | 7.490 |
Why?
| | Glomerular Filtration Rate | 86 | 2023 | 604 | 6.290 |
Why?
| | Renal Dialysis | 33 | 2023 | 374 | 5.670 |
Why?
| | Kidney | 45 | 2023 | 1188 | 5.320 |
Why?
| | Fibroblast Growth Factors | 25 | 2020 | 162 | 5.190 |
Why?
| | Cardiovascular Diseases | 57 | 2023 | 1727 | 4.800 |
Why?
| | Kidney Diseases | 31 | 2023 | 350 | 4.570 |
Why?
| | Vitamin D | 31 | 2022 | 341 | 4.150 |
Why?
| | Hypertension | 37 | 2022 | 1056 | 3.140 |
Why?
| | Vitamin D Deficiency | 12 | 2018 | 158 | 2.610 |
Why?
| | Vascular Stiffness | 17 | 2023 | 407 | 2.430 |
Why?
| | Endothelium, Vascular | 17 | 2021 | 847 | 2.410 |
Why?
| | Blood Pressure | 35 | 2023 | 1538 | 2.390 |
Why?
| | Aged | 168 | 2023 | 19074 | 2.210 |
Why?
| | Phosphorus | 13 | 2017 | 82 | 2.130 |
Why?
| | Middle Aged | 158 | 2023 | 26738 | 1.960 |
Why?
| | Uric Acid | 12 | 2021 | 148 | 1.950 |
Why?
| | Nephrology | 5 | 2022 | 48 | 1.950 |
Why?
| | Male | 220 | 2023 | 55606 | 1.930 |
Why?
| | Female | 220 | 2023 | 59520 | 1.860 |
Why?
| | Creatinine | 25 | 2021 | 425 | 1.830 |
Why?
| | Humans | 291 | 2023 | 114699 | 1.830 |
Why?
| | Disease Progression | 40 | 2023 | 2380 | 1.730 |
Why?
| | Risk Factors | 87 | 2022 | 8632 | 1.670 |
Why?
| | Phosphates | 11 | 2021 | 159 | 1.640 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 4 | 2020 | 11 | 1.610 |
Why?
| | Cholecalciferol | 5 | 2022 | 47 | 1.600 |
Why?
| | Parathyroid Hormone | 18 | 2020 | 96 | 1.580 |
Why?
| | Double-Blind Method | 30 | 2023 | 1660 | 1.510 |
Why?
| | Dietary Supplements | 10 | 2021 | 460 | 1.500 |
Why?
| | Vascular Calcification | 8 | 2022 | 107 | 1.480 |
Why?
| | Calcium | 13 | 2020 | 1108 | 1.290 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2023 | 373 | 1.260 |
Why?
| | Nutrition Surveys | 13 | 2015 | 224 | 1.260 |
Why?
| | Kidney Calculi | 3 | 2013 | 30 | 1.250 |
Why?
| | Biomarkers | 41 | 2022 | 3408 | 1.250 |
Why?
| | Antihypertensive Agents | 14 | 2021 | 429 | 1.250 |
Why?
| | Fatty Liver | 10 | 2013 | 211 | 1.220 |
Why?
| | Oxidative Stress | 16 | 2023 | 1076 | 1.210 |
Why?
| | Inflammation | 19 | 2022 | 2480 | 1.190 |
Why?
| | Brachial Artery | 11 | 2018 | 176 | 1.170 |
Why?
| | Blood Vessels | 3 | 2019 | 180 | 1.150 |
Why?
| | Adult | 74 | 2023 | 30553 | 1.150 |
Why?
| | Coronary Disease | 7 | 2010 | 348 | 1.140 |
Why?
| | Naphthalenes | 4 | 2015 | 38 | 1.130 |
Why?
| | Bacterial Infections | 3 | 2016 | 218 | 1.130 |
Why?
| | Prospective Studies | 41 | 2023 | 6220 | 1.060 |
Why?
| | Coronary Artery Disease | 11 | 2022 | 607 | 1.060 |
Why?
| | Adrenergic beta-Antagonists | 7 | 2011 | 287 | 1.040 |
Why?
| | Vascular Diseases | 7 | 2021 | 230 | 1.040 |
Why?
| | Pulse Wave Analysis | 10 | 2023 | 207 | 1.010 |
Why?
| | Cognition | 6 | 2023 | 989 | 1.010 |
Why?
| | Acute Kidney Injury | 10 | 2022 | 638 | 1.000 |
Why?
| | Cross-Sectional Studies | 37 | 2022 | 4410 | 1.000 |
Why?
| | Hyperparathyroidism, Secondary | 4 | 2009 | 9 | 0.970 |
Why?
| | Prevalence | 25 | 2018 | 2251 | 0.970 |
Why?
| | Minerals | 6 | 2022 | 37 | 0.930 |
Why?
| | Curcumin | 2 | 2021 | 28 | 0.890 |
Why?
| | Aged, 80 and over | 43 | 2023 | 6347 | 0.890 |
Why?
| | Cognitive Dysfunction | 2 | 2018 | 284 | 0.870 |
Why?
| | Pregnancy Complications | 3 | 2018 | 429 | 0.870 |
Why?
| | Follow-Up Studies | 37 | 2020 | 4411 | 0.870 |
Why?
| | Anemia | 5 | 2020 | 143 | 0.850 |
Why?
| | Proportional Hazards Models | 30 | 2019 | 1075 | 0.850 |
Why?
| | Cohort Studies | 31 | 2021 | 4895 | 0.840 |
Why?
| | Incidence | 28 | 2021 | 2313 | 0.840 |
Why?
| | Albuminuria | 13 | 2022 | 164 | 0.820 |
Why?
| | Vascular Surgical Procedures | 13 | 2011 | 259 | 0.800 |
Why?
| | Atherosclerosis | 8 | 2021 | 341 | 0.800 |
Why?
| | Sodium, Dietary | 3 | 2018 | 36 | 0.790 |
Why?
| | Non-alcoholic Fatty Liver Disease | 9 | 2016 | 245 | 0.780 |
Why?
| | Kidney Transplantation | 3 | 2022 | 541 | 0.760 |
Why?
| | Renal Insufficiency | 6 | 2023 | 137 | 0.750 |
Why?
| | Kidney Function Tests | 12 | 2017 | 140 | 0.730 |
Why?
| | Vitamins | 3 | 2022 | 151 | 0.730 |
Why?
| | Vasodilation | 6 | 2018 | 419 | 0.730 |
Why?
| | Calcimimetic Agents | 1 | 2020 | 2 | 0.720 |
Why?
| | Hyponatremia | 2 | 2018 | 37 | 0.720 |
Why?
| | Time Factors | 30 | 2022 | 6116 | 0.720 |
Why?
| | Sodium | 2 | 2019 | 183 | 0.710 |
Why?
| | Potassium, Dietary | 2 | 2018 | 10 | 0.710 |
Why?
| | Cystatin C | 7 | 2013 | 62 | 0.710 |
Why?
| | Calcitriol | 2 | 2018 | 53 | 0.700 |
Why?
| | Prognosis | 27 | 2021 | 3329 | 0.700 |
Why?
| | Systole | 8 | 2020 | 171 | 0.690 |
Why?
| | Bicarbonates | 5 | 2023 | 41 | 0.690 |
Why?
| | Renin-Angiotensin System | 3 | 2017 | 72 | 0.680 |
Why?
| | Renal Artery Obstruction | 3 | 2014 | 29 | 0.680 |
Why?
| | Bone Diseases | 1 | 2020 | 57 | 0.680 |
Why?
| | Overweight | 2 | 2021 | 472 | 0.680 |
Why?
| | Sodium Bicarbonate | 2 | 2023 | 40 | 0.670 |
Why?
| | Treatment Outcome | 38 | 2021 | 9088 | 0.660 |
Why?
| | Cause of Death | 6 | 2018 | 361 | 0.640 |
Why?
| | Interleukin-1 | 3 | 2019 | 966 | 0.640 |
Why?
| | Chronic Disease | 19 | 2017 | 1578 | 0.640 |
Why?
| | Spironolactone | 1 | 2019 | 28 | 0.630 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 38 | 0.630 |
Why?
| | Odds Ratio | 12 | 2017 | 953 | 0.630 |
Why?
| | Endothelial Cells | 5 | 2023 | 687 | 0.620 |
Why?
| | Accidental Falls | 1 | 2020 | 151 | 0.620 |
Why?
| | Obesity | 4 | 2021 | 2508 | 0.610 |
Why?
| | Hemoglobins | 4 | 2009 | 315 | 0.610 |
Why?
| | Acidosis | 2 | 2018 | 88 | 0.610 |
Why?
| | Simvastatin | 3 | 2014 | 59 | 0.610 |
Why?
| | Hypertrophy, Left Ventricular | 4 | 2017 | 102 | 0.610 |
Why?
| | Heart Diseases | 4 | 2015 | 331 | 0.610 |
Why?
| | Frailty | 1 | 2020 | 115 | 0.600 |
Why?
| | Interleukin-6 | 3 | 2020 | 676 | 0.600 |
Why?
| | Calcium, Dietary | 2 | 2009 | 55 | 0.600 |
Why?
| | Death, Sudden, Cardiac | 5 | 2015 | 160 | 0.600 |
Why?
| | United States | 33 | 2020 | 12186 | 0.590 |
Why?
| | Arterial Pressure | 1 | 2018 | 99 | 0.590 |
Why?
| | Metformin | 1 | 2021 | 276 | 0.590 |
Why?
| | Recombinant Fusion Proteins | 2 | 2017 | 616 | 0.580 |
Why?
| | Longitudinal Studies | 17 | 2020 | 2387 | 0.580 |
Why?
| | Carotid Artery Diseases | 3 | 2021 | 57 | 0.570 |
Why?
| | Multivariate Analysis | 14 | 2017 | 1430 | 0.560 |
Why?
| | Pregnancy Outcome | 3 | 2018 | 337 | 0.560 |
Why?
| | Bone Density | 5 | 2017 | 432 | 0.550 |
Why?
| | Young Adult | 20 | 2023 | 10471 | 0.550 |
Why?
| | Calcinosis | 6 | 2017 | 242 | 0.550 |
Why?
| | Conservative Treatment | 1 | 2017 | 29 | 0.540 |
Why?
| | Calciphylaxis | 1 | 2016 | 2 | 0.540 |
Why?
| | Diabetic Nephropathies | 5 | 2013 | 234 | 0.530 |
Why?
| | Uremia | 1 | 2016 | 14 | 0.530 |
Why?
| | Logistic Models | 11 | 2017 | 1841 | 0.530 |
Why?
| | Kidney Tubules | 4 | 2022 | 107 | 0.520 |
Why?
| | Diabetes Mellitus, Type 2 | 10 | 2012 | 2096 | 0.520 |
Why?
| | Sodium Chloride | 1 | 2017 | 136 | 0.520 |
Why?
| | Primary Prevention | 3 | 2018 | 172 | 0.520 |
Why?
| | Myocardial Infarction | 10 | 2017 | 927 | 0.520 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 179 | 0.510 |
Why?
| | Fluid Therapy | 1 | 2017 | 123 | 0.510 |
Why?
| | Liver | 2 | 2016 | 1637 | 0.510 |
Why?
| | Hyperuricemia | 5 | 2018 | 43 | 0.510 |
Why?
| | Diet, Sodium-Restricted | 4 | 2020 | 34 | 0.500 |
Why?
| | Peripheral Arterial Disease | 7 | 2021 | 380 | 0.500 |
Why?
| | Comorbidity | 13 | 2018 | 1448 | 0.490 |
Why?
| | Peripheral Vascular Diseases | 7 | 2012 | 97 | 0.490 |
Why?
| | Ventricular Dysfunction, Left | 6 | 2014 | 358 | 0.490 |
Why?
| | Undocumented Immigrants | 3 | 2023 | 41 | 0.480 |
Why?
| | Diabetes Complications | 6 | 2018 | 211 | 0.480 |
Why?
| | Risk Assessment | 24 | 2021 | 2968 | 0.480 |
Why?
| | Survival Rate | 14 | 2020 | 1644 | 0.480 |
Why?
| | Pyrazoles | 2 | 2014 | 362 | 0.470 |
Why?
| | Fructose | 2 | 2016 | 100 | 0.470 |
Why?
| | Retrospective Studies | 32 | 2020 | 12555 | 0.460 |
Why?
| | Cardiovascular Agents | 4 | 2013 | 126 | 0.460 |
Why?
| | Pyridines | 2 | 2014 | 425 | 0.460 |
Why?
| | Hyperphosphatemia | 4 | 2020 | 14 | 0.440 |
Why?
| | Ankle Brachial Index | 4 | 2014 | 30 | 0.430 |
Why?
| | C-Reactive Protein | 8 | 2018 | 362 | 0.430 |
Why?
| | Sodium Nitrite | 3 | 2021 | 37 | 0.430 |
Why?
| | Pneumonia, Bacterial | 1 | 2014 | 106 | 0.420 |
Why?
| | TRPP Cation Channels | 5 | 2022 | 63 | 0.420 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 141 | 0.410 |
Why?
| | Nephrolithiasis | 1 | 2012 | 10 | 0.410 |
Why?
| | Randomized Controlled Trials as Topic | 11 | 2021 | 1214 | 0.410 |
Why?
| | Hemostasis | 2 | 2009 | 67 | 0.400 |
Why?
| | Lanthanum | 3 | 2021 | 8 | 0.400 |
Why?
| | Radius | 1 | 2012 | 33 | 0.400 |
Why?
| | Caloric Restriction | 3 | 2023 | 90 | 0.400 |
Why?
| | Magnesium | 2 | 2014 | 145 | 0.400 |
Why?
| | Metabolic Syndrome | 6 | 2014 | 321 | 0.390 |
Why?
| | Chi-Square Distribution | 10 | 2017 | 493 | 0.390 |
Why?
| | Internship and Residency | 2 | 2020 | 926 | 0.390 |
Why?
| | Carotid Arteries | 4 | 2018 | 180 | 0.390 |
Why?
| | Coronary Artery Bypass | 3 | 2014 | 196 | 0.380 |
Why?
| | Health Status | 3 | 2015 | 722 | 0.380 |
Why?
| | Heart Ventricles | 2 | 2013 | 712 | 0.380 |
Why?
| | Resistance Training | 2 | 2023 | 113 | 0.380 |
Why?
| | Disease Management | 1 | 2015 | 560 | 0.380 |
Why?
| | Dementia | 3 | 2023 | 187 | 0.380 |
Why?
| | Independent Living | 5 | 2018 | 84 | 0.370 |
Why?
| | Hypothyroidism | 2 | 2009 | 64 | 0.370 |
Why?
| | Health Surveys | 3 | 2014 | 443 | 0.370 |
Why?
| | Case-Control Studies | 11 | 2021 | 3003 | 0.370 |
Why?
| | Kaplan-Meier Estimate | 14 | 2018 | 811 | 0.370 |
Why?
| | Insulin Resistance | 6 | 2013 | 1072 | 0.370 |
Why?
| | Physical Fitness | 1 | 2012 | 179 | 0.360 |
Why?
| | NAD | 2 | 2023 | 63 | 0.360 |
Why?
| | Weight Loss | 1 | 2015 | 642 | 0.350 |
Why?
| | Blood Coagulation Disorders | 2 | 2010 | 197 | 0.350 |
Why?
| | Hospitalization | 3 | 2016 | 1752 | 0.350 |
Why?
| | Homeostasis | 5 | 2018 | 573 | 0.350 |
Why?
| | Mortality | 5 | 2020 | 287 | 0.350 |
Why?
| | Hip Fractures | 3 | 2017 | 75 | 0.350 |
Why?
| | Ischemia | 3 | 2011 | 362 | 0.340 |
Why?
| | Zinc | 1 | 2012 | 260 | 0.340 |
Why?
| | Dyslipidemias | 2 | 2013 | 154 | 0.340 |
Why?
| | Body Mass Index | 9 | 2017 | 1959 | 0.340 |
Why?
| | Polycystic Kidney Diseases | 2 | 2023 | 55 | 0.340 |
Why?
| | Lovastatin | 1 | 2009 | 26 | 0.340 |
Why?
| | Blood Coagulation | 3 | 2011 | 218 | 0.330 |
Why?
| | gamma-Glutamyltransferase | 1 | 2009 | 42 | 0.330 |
Why?
| | Endocrine System Diseases | 1 | 2009 | 30 | 0.330 |
Why?
| | Hospitals, Veterans | 2 | 2008 | 244 | 0.320 |
Why?
| | Regional Blood Flow | 5 | 2017 | 424 | 0.310 |
Why?
| | Uromodulin | 5 | 2022 | 21 | 0.310 |
Why?
| | Fibrinolysis | 2 | 2011 | 158 | 0.310 |
Why?
| | Bilirubin | 1 | 2009 | 88 | 0.310 |
Why?
| | Severity of Illness Index | 12 | 2020 | 2540 | 0.310 |
Why?
| | Sepsis | 1 | 2014 | 509 | 0.310 |
Why?
| | Bone and Bones | 2 | 2012 | 279 | 0.300 |
Why?
| | Adolescent | 14 | 2023 | 17853 | 0.300 |
Why?
| | Patient Navigation | 2 | 2019 | 64 | 0.300 |
Why?
| | Diet | 2 | 2012 | 1080 | 0.300 |
Why?
| | Aging | 4 | 2021 | 1618 | 0.300 |
Why?
| | Phosphorus Metabolism Disorders | 1 | 2007 | 1 | 0.300 |
Why?
| | Ultrasonography | 6 | 2013 | 634 | 0.290 |
Why?
| | Metabolomics | 4 | 2022 | 521 | 0.290 |
Why?
| | Coronary Angiography | 3 | 2012 | 304 | 0.290 |
Why?
| | Brain | 2 | 2018 | 2371 | 0.280 |
Why?
| | Aorta | 3 | 2021 | 386 | 0.280 |
Why?
| | Aortic Aneurysm, Abdominal | 6 | 2011 | 113 | 0.280 |
Why?
| | Pravastatin | 2 | 2023 | 28 | 0.270 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2018 | 76 | 0.270 |
Why?
| | Infant Mortality | 2 | 2018 | 91 | 0.270 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2020 | 663 | 0.260 |
Why?
| | Lipocalin-2 | 3 | 2022 | 61 | 0.260 |
Why?
| | Thrombosis | 1 | 2009 | 298 | 0.260 |
Why?
| | Infant, Low Birth Weight | 2 | 2018 | 125 | 0.260 |
Why?
| | Electric Countershock | 1 | 2007 | 104 | 0.260 |
Why?
| | Professional Competence | 1 | 2006 | 81 | 0.260 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 3 | 2020 | 35 | 0.260 |
Why?
| | Coronary Vessels | 3 | 2022 | 227 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 5 | 2021 | 3053 | 0.260 |
Why?
| | Fasting | 4 | 2023 | 241 | 0.250 |
Why?
| | Cross-Over Studies | 5 | 2018 | 440 | 0.250 |
Why?
| | Anticholesteremic Agents | 1 | 2007 | 128 | 0.250 |
Why?
| | Quality of Life | 4 | 2020 | 2353 | 0.240 |
Why?
| | Respiratory Muscles | 2 | 2023 | 28 | 0.240 |
Why?
| | Deoxycholic Acid | 3 | 2022 | 15 | 0.240 |
Why?
| | Diabetes Mellitus, Type 1 | 7 | 2014 | 3252 | 0.240 |
Why?
| | Tryptophan | 2 | 2023 | 136 | 0.240 |
Why?
| | Cognition Disorders | 3 | 2017 | 476 | 0.240 |
Why?
| | Blood Pressure Determination | 3 | 2020 | 122 | 0.240 |
Why?
| | Survival Analysis | 6 | 2019 | 1211 | 0.240 |
Why?
| | Pre-Eclampsia | 2 | 2018 | 165 | 0.240 |
Why?
| | Nitric Oxide | 5 | 2023 | 823 | 0.240 |
Why?
| | Mitochondria | 2 | 2021 | 747 | 0.230 |
Why?
| | Animals | 15 | 2023 | 31708 | 0.230 |
Why?
| | Linear Models | 6 | 2017 | 768 | 0.220 |
Why?
| | Nutritional Status | 2 | 2018 | 287 | 0.220 |
Why?
| | Nephrotic Syndrome | 1 | 2003 | 24 | 0.220 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 299 | 0.220 |
Why?
| | Atrial Fibrillation | 2 | 2020 | 322 | 0.220 |
Why?
| | Diet, Ketogenic | 1 | 2023 | 33 | 0.220 |
Why?
| | Metabolome | 3 | 2022 | 282 | 0.210 |
Why?
| | Colorado | 9 | 2021 | 4100 | 0.210 |
Why?
| | Child | 9 | 2023 | 18420 | 0.210 |
Why?
| | Confidence Intervals | 3 | 2012 | 305 | 0.210 |
Why?
| | Recovery of Function | 3 | 2017 | 574 | 0.210 |
Why?
| | Drug Therapy, Combination | 6 | 2020 | 951 | 0.210 |
Why?
| | Human Umbilical Vein Endothelial Cells | 2 | 2021 | 89 | 0.210 |
Why?
| | Guideline Adherence | 1 | 2006 | 490 | 0.200 |
Why?
| | Heart Failure | 8 | 2017 | 1945 | 0.200 |
Why?
| | Compassion Fatigue | 1 | 2022 | 22 | 0.200 |
Why?
| | Military Personnel | 1 | 2009 | 524 | 0.200 |
Why?
| | Physicians | 2 | 2022 | 772 | 0.200 |
Why?
| | Antioxidants | 2 | 2018 | 530 | 0.200 |
Why?
| | Up-Regulation | 5 | 2019 | 808 | 0.200 |
Why?
| | Troponin T | 3 | 2012 | 49 | 0.200 |
Why?
| | Diastole | 3 | 2013 | 130 | 0.200 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2014 | 226 | 0.200 |
Why?
| | Exercise Tolerance | 1 | 2023 | 213 | 0.200 |
Why?
| | Diabetes Mellitus | 4 | 2020 | 900 | 0.190 |
Why?
| | Predictive Value of Tests | 11 | 2019 | 1796 | 0.190 |
Why?
| | Niacinamide | 2 | 2020 | 63 | 0.190 |
Why?
| | Breathing Exercises | 1 | 2021 | 18 | 0.190 |
Why?
| | Inhalation | 1 | 2021 | 26 | 0.190 |
Why?
| | Attitude of Health Personnel | 2 | 2018 | 975 | 0.190 |
Why?
| | Feasibility Studies | 2 | 2021 | 740 | 0.190 |
Why?
| | Propensity Score | 2 | 2019 | 224 | 0.180 |
Why?
| | Stroke | 4 | 2017 | 1022 | 0.180 |
Why?
| | Toxins, Biological | 1 | 2020 | 11 | 0.180 |
Why?
| | Culturally Competent Care | 1 | 2021 | 48 | 0.180 |
Why?
| | Neutrophils | 1 | 2006 | 1176 | 0.180 |
Why?
| | Parathyroidectomy | 1 | 2020 | 7 | 0.180 |
Why?
| | Education | 2 | 2018 | 95 | 0.180 |
Why?
| | Motor Activity | 2 | 2015 | 640 | 0.180 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2018 | 65 | 0.180 |
Why?
| | Osteoporotic Fractures | 2 | 2012 | 56 | 0.180 |
Why?
| | Communication Barriers | 1 | 2021 | 89 | 0.180 |
Why?
| | Intestinal Absorption | 1 | 2021 | 93 | 0.180 |
Why?
| | Plaque, Atherosclerotic | 1 | 2021 | 44 | 0.180 |
Why?
| | Propanolamines | 2 | 2011 | 90 | 0.180 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1079 | 0.180 |
Why?
| | Netherlands | 8 | 2012 | 64 | 0.180 |
Why?
| | Sevelamer | 1 | 2020 | 9 | 0.170 |
Why?
| | Allopurinol | 2 | 2018 | 53 | 0.170 |
Why?
| | Focus Groups | 2 | 2020 | 383 | 0.170 |
Why?
| | Cerebrovascular Circulation | 2 | 2023 | 221 | 0.170 |
Why?
| | Placebos | 2 | 2012 | 197 | 0.170 |
Why?
| | Hypokalemia | 1 | 2020 | 24 | 0.170 |
Why?
| | Age Factors | 8 | 2018 | 2894 | 0.170 |
Why?
| | Hyperkalemia | 1 | 2020 | 26 | 0.170 |
Why?
| | Tunica Intima | 3 | 2010 | 78 | 0.170 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2020 | 83 | 0.170 |
Why?
| | Organ Size | 2 | 2017 | 436 | 0.170 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 646 | 0.170 |
Why?
| | Age Distribution | 2 | 2012 | 342 | 0.170 |
Why?
| | Pilot Projects | 3 | 2020 | 1373 | 0.170 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 213 | 0.170 |
Why?
| | Preoperative Period | 4 | 2014 | 103 | 0.170 |
Why?
| | Sex Distribution | 2 | 2012 | 337 | 0.170 |
Why?
| | Acetates | 1 | 2020 | 95 | 0.170 |
Why?
| | Patient Care Planning | 1 | 2020 | 139 | 0.160 |
Why?
| | Mice | 8 | 2023 | 14871 | 0.160 |
Why?
| | Infant, Newborn | 4 | 2018 | 5047 | 0.160 |
Why?
| | Neuroimaging | 2 | 2018 | 249 | 0.160 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 75 | 0.160 |
Why?
| | Postoperative Complications | 6 | 2014 | 2128 | 0.160 |
Why?
| | Calcification, Physiologic | 1 | 2018 | 34 | 0.160 |
Why?
| | Reactive Oxygen Species | 4 | 2023 | 531 | 0.150 |
Why?
| | Health Services Accessibility | 3 | 2021 | 763 | 0.150 |
Why?
| | Carnitine | 1 | 2018 | 62 | 0.150 |
Why?
| | Fellowships and Scholarships | 2 | 2020 | 227 | 0.150 |
Why?
| | Electrocardiography | 5 | 2020 | 560 | 0.150 |
Why?
| | Potassium | 2 | 2020 | 128 | 0.150 |
Why?
| | Scandinavian and Nordic Countries | 2 | 2008 | 6 | 0.150 |
Why?
| | Information Seeking Behavior | 1 | 2018 | 35 | 0.150 |
Why?
| | Pain | 2 | 2020 | 705 | 0.150 |
Why?
| | Cholesterol, HDL | 4 | 2013 | 183 | 0.150 |
Why?
| | Healthy Aging | 1 | 2018 | 18 | 0.150 |
Why?
| | Healthy Lifestyle | 1 | 2018 | 30 | 0.150 |
Why?
| | Bone Diseases, Metabolic | 1 | 2018 | 53 | 0.140 |
Why?
| | Peer Group | 1 | 2019 | 201 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2022 | 322 | 0.140 |
Why?
| | Death | 1 | 2018 | 107 | 0.140 |
Why?
| | Adaptive Immunity | 1 | 2018 | 155 | 0.140 |
Why?
| | Emergency Treatment | 1 | 2018 | 113 | 0.140 |
Why?
| | Femoral Artery | 1 | 2018 | 167 | 0.140 |
Why?
| | Hemodialysis Solutions | 1 | 2017 | 3 | 0.140 |
Why?
| | Preoperative Care | 2 | 2010 | 319 | 0.140 |
Why?
| | Neuropsychological Tests | 2 | 2018 | 927 | 0.140 |
Why?
| | Liver Transplantation | 1 | 2003 | 707 | 0.140 |
Why?
| | Energy Metabolism | 1 | 2022 | 731 | 0.140 |
Why?
| | Vasopressins | 1 | 2017 | 56 | 0.130 |
Why?
| | Cholesterol, LDL | 3 | 2013 | 307 | 0.130 |
Why?
| | Mutation | 3 | 2022 | 3346 | 0.130 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2013 | 16 | 0.130 |
Why?
| | Living Donors | 1 | 2018 | 270 | 0.130 |
Why?
| | Congenital Abnormalities | 1 | 2017 | 73 | 0.130 |
Why?
| | Immunity, Humoral | 1 | 2017 | 112 | 0.130 |
Why?
| | Pregnancy | 3 | 2018 | 5520 | 0.130 |
Why?
| | Bile Acids and Salts | 1 | 2017 | 171 | 0.130 |
Why?
| | Trehalose | 1 | 2016 | 30 | 0.130 |
Why?
| | Postoperative Period | 3 | 2011 | 289 | 0.130 |
Why?
| | Heart Rate | 2 | 2011 | 709 | 0.130 |
Why?
| | Vascular Resistance | 2 | 2014 | 337 | 0.130 |
Why?
| | Heart Arrest | 2 | 2016 | 293 | 0.130 |
Why?
| | Global Health | 2 | 2015 | 287 | 0.130 |
Why?
| | Lipogenesis | 1 | 2016 | 56 | 0.130 |
Why?
| | Absorptiometry, Photon | 2 | 2017 | 224 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2017 | 248 | 0.130 |
Why?
| | Communicable Diseases | 1 | 2017 | 129 | 0.130 |
Why?
| | Risk Reduction Behavior | 2 | 2015 | 201 | 0.130 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2015 | 53 | 0.130 |
Why?
| | Phosphatidylethanolamines | 1 | 2015 | 66 | 0.120 |
Why?
| | Heart Valve Diseases | 1 | 2017 | 161 | 0.120 |
Why?
| | Peptides | 1 | 2020 | 848 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 134 | 0.120 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2015 | 91 | 0.120 |
Why?
| | Analysis of Variance | 3 | 2012 | 1226 | 0.120 |
Why?
| | Frail Elderly | 1 | 2016 | 106 | 0.120 |
Why?
| | Maternal Mortality | 1 | 2015 | 30 | 0.120 |
Why?
| | Obstetric Labor, Premature | 1 | 2015 | 33 | 0.120 |
Why?
| | Risk | 5 | 2019 | 812 | 0.120 |
Why?
| | Aorta, Abdominal | 2 | 2012 | 39 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2013 | 1842 | 0.120 |
Why?
| | Metabolic Diseases | 2 | 2014 | 98 | 0.120 |
Why?
| | Fibroblast Growth Factor 3 | 1 | 2014 | 3 | 0.120 |
Why?
| | Serine | 1 | 2015 | 126 | 0.120 |
Why?
| | Italy | 5 | 2014 | 92 | 0.120 |
Why?
| | Acetylcholine | 3 | 2023 | 166 | 0.120 |
Why?
| | Estrogen Replacement Therapy | 2 | 2014 | 116 | 0.120 |
Why?
| | 24,25-Dihydroxyvitamin D 3 | 1 | 2014 | 2 | 0.120 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 448 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2020 | 501 | 0.120 |
Why?
| | Transcription Factor CHOP | 1 | 2014 | 28 | 0.120 |
Why?
| | Renal Artery | 1 | 2014 | 26 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1262 | 0.120 |
Why?
| | Inflammation Mediators | 1 | 2017 | 477 | 0.120 |
Why?
| | Infant, Small for Gestational Age | 1 | 2015 | 76 | 0.110 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 5 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2019 | 480 | 0.110 |
Why?
| | Organophosphonates | 1 | 2014 | 90 | 0.110 |
Why?
| | Sex Factors | 5 | 2018 | 1715 | 0.110 |
Why?
| | Endothelium | 1 | 2014 | 111 | 0.110 |
Why?
| | Sodium Chloride, Dietary | 1 | 2014 | 30 | 0.110 |
Why?
| | Tocopherols | 1 | 2013 | 22 | 0.110 |
Why?
| | Steroid Hydroxylases | 1 | 2013 | 19 | 0.110 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2013 | 25 | 0.110 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.110 |
Why?
| | Premature Birth | 1 | 2017 | 276 | 0.110 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 90 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 368 | 0.110 |
Why?
| | Glucose | 1 | 2018 | 897 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 687 | 0.110 |
Why?
| | Statistics as Topic | 2 | 2017 | 292 | 0.110 |
Why?
| | Cesarean Section | 1 | 2015 | 169 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 750 | 0.110 |
Why?
| | Hypercapnia | 2 | 2023 | 51 | 0.100 |
Why?
| | Aortic Valve Stenosis | 2 | 2017 | 272 | 0.100 |
Why?
| | Adenine | 1 | 2014 | 219 | 0.100 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 176 | 0.100 |
Why?
| | Ferric Compounds | 1 | 2012 | 41 | 0.100 |
Why?
| | Institutionalization | 1 | 2012 | 12 | 0.100 |
Why?
| | Glycation End Products, Advanced | 1 | 2012 | 57 | 0.100 |
Why?
| | Endoplasmic Reticulum | 1 | 2014 | 234 | 0.100 |
Why?
| | Cytokines | 2 | 2018 | 1841 | 0.100 |
Why?
| | Causality | 2 | 2011 | 103 | 0.100 |
Why?
| | Spinal Fractures | 1 | 2013 | 75 | 0.100 |
Why?
| | Kynurenine | 2 | 2023 | 81 | 0.100 |
Why?
| | Postoperative Care | 2 | 2010 | 222 | 0.100 |
Why?
| | Aortic Aneurysm | 1 | 2012 | 55 | 0.100 |
Why?
| | Tunica Media | 2 | 2010 | 35 | 0.100 |
Why?
| | Echocardiography, Stress | 2 | 2010 | 20 | 0.100 |
Why?
| | Sympathetic Nervous System | 2 | 2015 | 171 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2177 | 0.100 |
Why?
| | Hospital Mortality | 2 | 2014 | 776 | 0.100 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 158 | 0.100 |
Why?
| | Dietary Fiber | 1 | 2011 | 40 | 0.090 |
Why?
| | International Classification of Diseases | 1 | 2012 | 116 | 0.090 |
Why?
| | Drug Combinations | 1 | 2012 | 287 | 0.090 |
Why?
| | Hemostatic Disorders | 1 | 2011 | 1 | 0.090 |
Why?
| | Infant, Premature | 1 | 2015 | 476 | 0.090 |
Why?
| | Qualitative Research | 3 | 2021 | 936 | 0.090 |
Why?
| | Muscle Strength | 2 | 2023 | 271 | 0.090 |
Why?
| | Cardiovascular System | 3 | 2020 | 125 | 0.090 |
Why?
| | Heart Failure, Systolic | 1 | 2010 | 20 | 0.090 |
Why?
| | Mice, Inbred C57BL | 4 | 2023 | 4694 | 0.090 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2010 | 94 | 0.090 |
Why?
| | Gout | 1 | 2010 | 36 | 0.090 |
Why?
| | Length of Stay | 1 | 2015 | 962 | 0.090 |
Why?
| | Carbazoles | 1 | 2010 | 78 | 0.090 |
Why?
| | Ticlopidine | 1 | 2010 | 55 | 0.090 |
Why?
| | Thinness | 1 | 2010 | 87 | 0.090 |
Why?
| | Alpha-Globulins | 2 | 2020 | 20 | 0.080 |
Why?
| | Aneurysm | 1 | 2009 | 29 | 0.080 |
Why?
| | beta 2-Microglobulin | 2 | 2020 | 45 | 0.080 |
Why?
| | Proteinuria | 2 | 2014 | 77 | 0.080 |
Why?
| | Delphi Technique | 2 | 2020 | 160 | 0.080 |
Why?
| | Nisoldipine | 1 | 2009 | 6 | 0.080 |
Why?
| | Enalapril | 1 | 2009 | 15 | 0.080 |
Why?
| | Arterial Occlusive Diseases | 1 | 2009 | 74 | 0.080 |
Why?
| | Texas | 1 | 2009 | 188 | 0.080 |
Why?
| | Genetic Loci | 1 | 2010 | 262 | 0.080 |
Why?
| | Cerebrovascular Disorders | 1 | 2009 | 82 | 0.080 |
Why?
| | Radioisotope Renography | 1 | 2008 | 4 | 0.080 |
Why?
| | Regression Analysis | 3 | 2019 | 945 | 0.080 |
Why?
| | Tomography, Spiral Computed | 1 | 2008 | 23 | 0.080 |
Why?
| | Infant | 3 | 2018 | 7964 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 67 | 0.080 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2008 | 33 | 0.080 |
Why?
| | Chelating Agents | 2 | 2020 | 65 | 0.080 |
Why?
| | Population Groups | 1 | 2009 | 57 | 0.080 |
Why?
| | Databases as Topic | 1 | 2008 | 63 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2014 | 795 | 0.080 |
Why?
| | Diabetic Retinopathy | 1 | 2010 | 149 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 785 | 0.070 |
Why?
| | Perindopril | 1 | 2007 | 1 | 0.070 |
Why?
| | Demography | 1 | 2009 | 260 | 0.070 |
Why?
| | Aspirin | 1 | 2010 | 324 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2023 | 2570 | 0.070 |
Why?
| | Endpoint Determination | 1 | 2008 | 68 | 0.070 |
Why?
| | Osteogenesis | 2 | 2021 | 183 | 0.070 |
Why?
| | Estradiol | 1 | 2010 | 455 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 321 | 0.070 |
Why?
| | Testosterone | 1 | 2010 | 343 | 0.070 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2010 | 401 | 0.070 |
Why?
| | Peptide Fragments | 1 | 2010 | 666 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 1 | 2008 | 220 | 0.070 |
Why?
| | Triglycerides | 3 | 2013 | 467 | 0.070 |
Why?
| | Forearm | 2 | 2017 | 112 | 0.060 |
Why?
| | Contrast Media | 1 | 2008 | 345 | 0.060 |
Why?
| | Protective Factors | 2 | 2016 | 87 | 0.060 |
Why?
| | Autoimmune Diseases | 1 | 2009 | 382 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 961 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2011 | 720 | 0.060 |
Why?
| | Outpatients | 1 | 2008 | 326 | 0.060 |
Why?
| | Models, Biological | 2 | 2014 | 1621 | 0.060 |
Why?
| | Phagocytosis | 1 | 2006 | 350 | 0.060 |
Why?
| | Genotype | 2 | 2020 | 1760 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 797 | 0.060 |
Why?
| | Respiratory Therapy | 1 | 2023 | 19 | 0.060 |
Why?
| | Hemodialysis, Home | 1 | 2023 | 8 | 0.060 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2023 | 9 | 0.060 |
Why?
| | Caregivers | 2 | 2020 | 717 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 53 | 0.050 |
Why?
| | Self-Help Groups | 1 | 2023 | 29 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2003 | 105 | 0.050 |
Why?
| | Kidney Glomerulus | 1 | 2003 | 100 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1879 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 22 | 0.050 |
Why?
| | Hand Strength | 1 | 2023 | 96 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 44 | 0.050 |
Why?
| | Muscles | 1 | 2023 | 320 | 0.050 |
Why?
| | NADPH Oxidases | 2 | 2013 | 120 | 0.050 |
Why?
| | Midazolam | 1 | 2022 | 43 | 0.050 |
Why?
| | Least-Squares Analysis | 2 | 2012 | 70 | 0.050 |
Why?
| | Waist Circumference | 2 | 2012 | 122 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2023 | 218 | 0.050 |
Why?
| | Endocannabinoids | 1 | 2022 | 36 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 139 | 0.050 |
Why?
| | Vulnerable Populations | 1 | 2022 | 134 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 916 | 0.050 |
Why?
| | Blood Flow Velocity | 1 | 2023 | 387 | 0.050 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 271 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 2797 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 932 | 0.050 |
Why?
| | Activating Transcription Factor 4 | 1 | 2021 | 18 | 0.050 |
Why?
| | Social Isolation | 1 | 2021 | 52 | 0.050 |
Why?
| | Hematinics | 1 | 2020 | 18 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2022 | 3535 | 0.050 |
Why?
| | Hepcidins | 1 | 2020 | 21 | 0.050 |
Why?
| | Acute Disease | 2 | 2017 | 911 | 0.050 |
Why?
| | Databases, Genetic | 1 | 2022 | 206 | 0.040 |
Why?
| | Nephrologists | 1 | 2020 | 12 | 0.040 |
Why?
| | HIV Infections | 1 | 2014 | 2469 | 0.040 |
Why?
| | Administrative Personnel | 1 | 2020 | 29 | 0.040 |
Why?
| | Social Stigma | 1 | 2021 | 87 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1121 | 0.040 |
Why?
| | Calcium Compounds | 1 | 2020 | 4 | 0.040 |
Why?
| | California | 2 | 2012 | 353 | 0.040 |
Why?
| | Asia | 1 | 2020 | 53 | 0.040 |
Why?
| | Biopsy | 1 | 2003 | 1036 | 0.040 |
Why?
| | Africa | 1 | 2020 | 94 | 0.040 |
Why?
| | Serum Albumin | 1 | 2020 | 137 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2021 | 172 | 0.040 |
Why?
| | Vitamin B Complex | 1 | 2020 | 38 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2021 | 184 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2020 | 73 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 33 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 412 | 0.040 |
Why?
| | Drug Interactions | 1 | 2021 | 338 | 0.040 |
Why?
| | Registries | 2 | 2021 | 1768 | 0.040 |
Why?
| | Models, Animal | 1 | 2021 | 344 | 0.040 |
Why?
| | Intracranial Aneurysm | 1 | 2020 | 91 | 0.040 |
Why?
| | Health Literacy | 1 | 2021 | 164 | 0.040 |
Why?
| | Urban Population | 1 | 2021 | 397 | 0.040 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2018 | 17 | 0.040 |
Why?
| | Ligands | 1 | 2020 | 562 | 0.040 |
Why?
| | Glucuronidase | 1 | 2018 | 42 | 0.040 |
Why?
| | Renal Circulation | 1 | 2018 | 53 | 0.040 |
Why?
| | Patients | 1 | 2020 | 163 | 0.040 |
Why?
| | Career Choice | 1 | 2020 | 177 | 0.040 |
Why?
| | Self Concept | 1 | 2020 | 214 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2018 | 105 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 186 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2018 | 38 | 0.040 |
Why?
| | Pyridinium Compounds | 1 | 2018 | 13 | 0.040 |
Why?
| | Sodium Chloride Symporter Inhibitors | 1 | 2018 | 9 | 0.040 |
Why?
| | Publications | 1 | 2018 | 37 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 250 | 0.040 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 144 | 0.040 |
Why?
| | Fibrosis | 1 | 2020 | 453 | 0.040 |
Why?
| | Fathers | 1 | 2018 | 45 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 537 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2020 | 349 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2018 | 114 | 0.040 |
Why?
| | NF-kappa B | 2 | 2012 | 641 | 0.040 |
Why?
| | Intelligence Tests | 1 | 2017 | 58 | 0.040 |
Why?
| | Cholesterol | 1 | 2019 | 367 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2018 | 197 | 0.040 |
Why?
| | Mitral Valve Stenosis | 1 | 2017 | 21 | 0.040 |
Why?
| | Interleukin-18 | 1 | 2018 | 219 | 0.040 |
Why?
| | Energy Intake | 1 | 2020 | 427 | 0.040 |
Why?
| | Safety-net Providers | 1 | 2018 | 95 | 0.030 |
Why?
| | Femur Neck | 1 | 2017 | 59 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2021 | 573 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 152 | 0.030 |
Why?
| | Diuretics | 1 | 2016 | 66 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2010 | 1693 | 0.030 |
Why?
| | Hip Joint | 1 | 2017 | 126 | 0.030 |
Why?
| | Methemoglobin | 1 | 2015 | 19 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2018 | 583 | 0.030 |
Why?
| | White Matter | 1 | 2017 | 105 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 833 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 347 | 0.030 |
Why?
| | Program Development | 1 | 2018 | 341 | 0.030 |
Why?
| | Anthropometry | 1 | 2016 | 183 | 0.030 |
Why?
| | Research | 1 | 2018 | 394 | 0.030 |
Why?
| | Research Design | 2 | 2011 | 928 | 0.030 |
Why?
| | Elasticity | 1 | 2015 | 189 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2019 | 578 | 0.030 |
Why?
| | Urinalysis | 1 | 2015 | 64 | 0.030 |
Why?
| | Vasodilator Agents | 1 | 2017 | 302 | 0.030 |
Why?
| | Prenatal Diagnosis | 1 | 2016 | 167 | 0.030 |
Why?
| | Renal Reabsorption | 1 | 2014 | 4 | 0.030 |
Why?
| | Renal Elimination | 1 | 2014 | 6 | 0.030 |
Why?
| | Age of Onset | 1 | 2016 | 446 | 0.030 |
Why?
| | Gastrointestinal Absorption | 1 | 2014 | 5 | 0.030 |
Why?
| | Needs Assessment | 1 | 2017 | 314 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 664 | 0.030 |
Why?
| | Actigraphy | 1 | 2015 | 75 | 0.030 |
Why?
| | Immunotherapy | 1 | 2018 | 474 | 0.030 |
Why?
| | Ketocholesterols | 1 | 2014 | 8 | 0.030 |
Why?
| | France | 1 | 2014 | 34 | 0.030 |
Why?
| | Health Personnel | 1 | 2020 | 574 | 0.030 |
Why?
| | Prostaglandins | 1 | 2014 | 77 | 0.030 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2014 | 39 | 0.030 |
Why?
| | Ezetimibe | 1 | 2014 | 24 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 55 | 0.030 |
Why?
| | Azetidines | 1 | 2014 | 31 | 0.030 |
Why?
| | Osteoporosis | 1 | 2017 | 226 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2014 | 80 | 0.030 |
Why?
| | F2-Isoprostanes | 1 | 2013 | 14 | 0.030 |
Why?
| | Erythropoiesis | 1 | 2013 | 33 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 13 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 16 | 0.030 |
Why?
| | Acute Coronary Syndrome | 1 | 2017 | 253 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2014 | 52 | 0.030 |
Why?
| | Signal Transduction | 2 | 2018 | 4515 | 0.030 |
Why?
| | Executive Function | 1 | 2018 | 380 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 3886 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2086 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 822 | 0.030 |
Why?
| | Pulse | 1 | 2013 | 27 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 1950 | 0.030 |
Why?
| | Tenofovir | 1 | 2014 | 204 | 0.030 |
Why?
| | Blood Glucose | 2 | 2012 | 1828 | 0.030 |
Why?
| | Aortic Valve | 1 | 2017 | 398 | 0.030 |
Why?
| | Immunoblotting | 1 | 2013 | 283 | 0.030 |
Why?
| | Insulin | 2 | 2013 | 2080 | 0.030 |
Why?
| | Cell Line | 1 | 2018 | 2637 | 0.030 |
Why?
| | Albumins | 1 | 2013 | 89 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2018 | 951 | 0.030 |
Why?
| | Random Allocation | 1 | 2013 | 335 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 397 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 718 | 0.030 |
Why?
| | Biological Availability | 1 | 2012 | 119 | 0.030 |
Why?
| | Xanthine Oxidase | 1 | 2012 | 71 | 0.030 |
Why?
| | Germany | 1 | 2012 | 84 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2020 | 944 | 0.030 |
Why?
| | Aspartate Aminotransferases | 1 | 2012 | 86 | 0.030 |
Why?
| | Mothers | 1 | 2018 | 651 | 0.020 |
Why?
| | Ventricular Remodeling | 1 | 2014 | 226 | 0.020 |
Why?
| | Microcirculation | 1 | 2012 | 135 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2013 | 1016 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2012 | 128 | 0.020 |
Why?
| | Perioperative Period | 1 | 2011 | 49 | 0.020 |
Why?
| | Metoprolol | 1 | 2011 | 37 | 0.020 |
Why?
| | Nitroglycerin | 1 | 2010 | 19 | 0.020 |
Why?
| | Stroke Volume | 1 | 2013 | 504 | 0.020 |
Why?
| | Aortic Diseases | 1 | 2012 | 106 | 0.020 |
Why?
| | Salicylates | 1 | 2010 | 30 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2012 | 339 | 0.020 |
Why?
| | Arteries | 1 | 2012 | 247 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 580 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 53 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 371 | 0.020 |
Why?
| | Sunlight | 1 | 2010 | 57 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2012 | 306 | 0.020 |
Why?
| | Area Under Curve | 1 | 2010 | 274 | 0.020 |
Why?
| | Life Style | 1 | 2012 | 430 | 0.020 |
Why?
| | Echocardiography | 1 | 2012 | 553 | 0.020 |
Why?
| | Elective Surgical Procedures | 1 | 2010 | 151 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2009 | 11 | 0.020 |
Why?
| | ROC Curve | 1 | 2010 | 442 | 0.020 |
Why?
| | Cystatins | 1 | 2008 | 7 | 0.020 |
Why?
| | Myocardial Ischemia | 1 | 2010 | 235 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2218 | 0.020 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2008 | 29 | 0.020 |
Why?
| | Dobutamine | 1 | 2007 | 33 | 0.020 |
Why?
| | Exercise | 1 | 2018 | 1644 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 1820 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 280 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1040 | 0.020 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2008 | 146 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2013 | 800 | 0.020 |
Why?
| | Perioperative Care | 1 | 2008 | 127 | 0.020 |
Why?
| | Hemodynamics | 1 | 2011 | 1012 | 0.020 |
Why?
| | Rats | 1 | 2013 | 4958 | 0.020 |
Why?
| | Ventricular Function, Left | 1 | 2007 | 467 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2012 | 1013 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1177 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 4624 | 0.010 |
Why?
|
|
Chonchol's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|